TY - JOUR
T1 - Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells
AU - Endo, Satoshi
AU - Xia, Shuang
AU - Suyama, Miho
AU - Morikawa, Yoshifumi
AU - Oguri, Hiroaki
AU - Hu, Dawei
AU - Ao, Yoshinori
AU - Takahara, Satoyuki
AU - Horino, Yoshikazu
AU - Hayakawa, Yoshihiro
AU - Watanabe, Yurie
AU - Gouda, Hiroaki
AU - Hara, Akira
AU - Kuwata, Kazuo
AU - Toyooka, Naoki
AU - Matsunaga, Toshiyuki
AU - Ikari, Akira
N1 - Publisher Copyright:
© 2017 American Chemical Society.
PY - 2017/10/26
Y1 - 2017/10/26
N2 - Aldo-keto reductase 1B10 (AKR1B10) is overexpressed in several extraintestinal cancers, particularly in non-small-cell lung cancer, where AKR1B10 is a potential diagnostic marker and therapeutic target. Selective AKR1B10 inhibitors are required because compounds should not inhibit the highly related aldose reductase that is involved in monosaccharide and prostaglandin metabolism. Currently, 7-hydroxy-2-(4-methoxyphenylimino)-2H-chromene-3-carboxylic acid benzylamide (HMPC) is known to be the most potent competitive inhibitor of AKR1B10, but it is nonselective. In this study, derivatives of HMPC were synthesized by removing the 4-methoxyphenylimino moiety and replacing the benzylamide with phenylpropylamide. Among them, 4c and 4e showed higher AKR1B10 inhibitory potency (IC50 4.2 and 3.5 nM, respectively) and selectivity than HMPC. The treatments with the two compounds significantly suppressed not only migration, proliferation, and metastasis of lung cancer A549 cells but also metastatic and invasive potentials of cisplatin-resistant A549 cells.
AB - Aldo-keto reductase 1B10 (AKR1B10) is overexpressed in several extraintestinal cancers, particularly in non-small-cell lung cancer, where AKR1B10 is a potential diagnostic marker and therapeutic target. Selective AKR1B10 inhibitors are required because compounds should not inhibit the highly related aldose reductase that is involved in monosaccharide and prostaglandin metabolism. Currently, 7-hydroxy-2-(4-methoxyphenylimino)-2H-chromene-3-carboxylic acid benzylamide (HMPC) is known to be the most potent competitive inhibitor of AKR1B10, but it is nonselective. In this study, derivatives of HMPC were synthesized by removing the 4-methoxyphenylimino moiety and replacing the benzylamide with phenylpropylamide. Among them, 4c and 4e showed higher AKR1B10 inhibitory potency (IC50 4.2 and 3.5 nM, respectively) and selectivity than HMPC. The treatments with the two compounds significantly suppressed not only migration, proliferation, and metastasis of lung cancer A549 cells but also metastatic and invasive potentials of cisplatin-resistant A549 cells.
UR - http://www.scopus.com/inward/record.url?scp=85032457802&partnerID=8YFLogxK
U2 - 10.1021/acs.jmedchem.7b00830
DO - 10.1021/acs.jmedchem.7b00830
M3 - 学術論文
C2 - 28976752
AN - SCOPUS:85032457802
SN - 0022-2623
VL - 60
SP - 8441
EP - 8455
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 20
ER -
